TeamDrive
RUS
Leonid Melamed

Leonid Melamed

Founding Partner, Chairman of The Board of Directors

Телефоны:

+7 495 545-39-12

Send message

​Leonid has almost 30 years of management experience at large companies in various market sectors.

Leonid – one of the leader of the team, implementing a major pharmaceutical and medical project, the brainchild of its investors RUSNANO OJSC and the American firm Domain Associates LLC. RusnanoMedInvest LLC (RMI) was founded to implement this project. RMI is the largest venture capital company in life sciences in Eastern Europe, focusing on innovative pharmaceutical projects backed by sustainable, cutting edge technologies. Russian pharmaceutical company NovaMedica LLC is responsible for the localisation of the products and technologies in Russia. It was also founded to implement ambitious plans to create a new GMP-compliant production facility and facilitate the production of innovative drugs.

Leonid Melamed is the co-founder and Chairman of the Board of Directors of RMI Partners (venture capital investment company), which manages the healthcare projects, one of them - a venture capital fund RusnanoMedInvest (RMI). One of the main investment in the RMI portfolio is NovaMedica LLC. At the present time Leonid is a member of the Board of Directors of RusnanoMedInvest and from 2012 to 2017 he was a member of the Board of NovaMedica.

Leonid also is the co-founder and member of the Board of Directors of Doctor Ryadom (network of medical clinics), which among the first in Russia began to provide telemedicine services to its patients.

Earlier Leonid was the President and Chairman of the Management Board and member of the Board of Directors of Sistema JFSC (from 2008 to 2011). From 2006 to 2008, Leonid ran the telecommunications company Mobile TeleSystems (MTS OJSC) as President and Chairman of the Management Board. For 15 years from 1991 to 2006 Leonid participated in the creation and development of ROSNO insurance company. In 2003 he was the head of ROSNO as CEO and Chairman of the Management Board.

His personal “portfolio” includes Russneft OJSC as Chairman of the Board of Directors (2010-2012) and VTB OJSC as a member of the Supervisory Board (2012-2013).

Currently, Leonid is a member of the Government Expert Council of the Russian Federation, which was established to involve the business community in the preparation and implementation of the Government’s decisions.

Leonid graduated with honours from I.M. Sechenov Moscow Medical Academy and in 2006 became a Doctor of Medical Sciences.

Media Center

  • 25 June 2018

    Researchers unveil “unprecedentedly sensitive” biochips

    Researchers at the Moscow Institute of Physics and Technology (MIPT), a top technology university in Russia, have developed new biosensor chips of “unprecedentedly high sensitivity.” They replaced gold, which is typically used in such devices, with copper. The approach is expected to not only lower the cost of the end solutions but also make biosensor manufacturing technology much simpler, the developers said. 

  • 25 June 2018

    No pharma Grand Prix—again—at Cannes Lions Health, but record number of awards for drugmakers

    For the second year in a row, there is no grand prize winner in the pharma category at Cannes Lions Health. The big idea award, called the Grand Prix, eluded the field again, despite a pharma-heavy short list. But while pharma marketers may be disappointed, they still have plenty of reason to celebrate. Sixteen different pharma companies made the awards shortlist and 10 won gold, silver or bronze Lions. That’s a sharp uptick from last year when only nine were finalists and three picked up awards.

  • 22 June 2018

    Drug shortages again on the rise after 5 years of improvements, FDA says

    After 5 years of declines in the number of new drug shortages in the U.S., they jumped to 39 last year from 26 in the two preceding years. And while that is a far cry from the peak of more than 250 registered in 2011, the FDA acknowledges that many of the current shortages have been for critical drug products and “are having a tangible impact on patients.”

  • 22 June 2018

    Pfizer’s 'Living With Cancer' wowed Cannes attendees, if not the pharma jury

    A Pfizer documentary film about five patients living with cancer may have inspired more fanfare at Cannes Lions Health than it did in the eight months since its launch. The “This is Living With Cancer” film and its associated campaign was shortlisted for a pharma award at the annual ad festival and was heaped with praise after Pfizer presented it in an open session.

Read more